Regeneron Pharmaceuticals, Inc. (REGN)
| Market Cap | 79.24B +2.1% |
| Revenue (ttm) | 14.34B +1.0% |
| Net Income | 4.50B +2.1% |
| EPS | 41.48 +8.2% |
| Shares Out | 102.62M |
| PE Ratio | 18.62 |
| Forward PE | 17.28 |
| Dividend | $3.76 (0.49%) |
| Ex-Dividend Date | Feb 20, 2026 |
| Volume | 628,622 |
| Open | 780.47 |
| Previous Close | 787.04 |
| Day's Range | 768.75 - 792.67 |
| 52-Week Range | 476.49 - 821.11 |
| Beta | 0.41 |
| Analysts | Buy |
| Price Target | 812.57 (+5.23%) |
| Earnings Date | Jan 30, 2026 |
About REGN
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent ... [Read more]
Financial Performance
In 2025, Regeneron Pharmaceuticals's revenue was $14.34 billion, an increase of 0.99% compared to the previous year's $14.20 billion. Earnings were $4.50 billion, an increase of 2.09%.
Financial StatementsAnalyst Summary
According to 23 analysts, the average rating for REGN stock is "Buy." The 12-month stock price target is $812.57, which is an increase of 5.23% from the latest price.
News
Regeneron, Sanofi Blockbuster Dupixent Scores FDA Nod For Rare Sinus Condition
• Regeneron Pharmaceuticals stock is facing resistance. Why are REGN shares declining?
Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)
Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery comp...
Press Release: Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis
Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Approval in adults and children aged 6 years and older supported by phase 3 study d...
Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability
Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial
Ocular Therapeutix said on Tuesday its experimental eye disease drug was more effective in helping patients maintain their vision compared to Regeneron's approved treatment Eylea in a late-stage trial...
Baird Chautauqua International Growth Fund: Q4 2025 Winners, Laggards, Buys & Sells
Baird Chautauqua International Growth Fund underperformed its benchmark as stock selection in health care and consumer discretionary detracted most from relative returns. Fanuc reported September quar...
Regeneron Announces Investor Conference Presentations
TARRYTOWN, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy
36 abstracts to be presented across Regeneron-invented therapies, including first-time Phase 3 presentations for two distinct investigational allergen-blocking antibodies for cat and birch allergies
These Analysts Revise Their Forecasts On Regeneron Pharmaceuticals After Q4 Results
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) on Friday reported upbeat fourth-quarter earnings.
EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases
New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase 3b ELARA trial in patients treated...
Regeneron: Expect Double-Digit Growth In 2026
Regeneron is poised for double-digit revenue and EPS growth in 2026, driven by Dupixent and reduced Eylea headwinds. Dupixent's robust expansion and pipeline successors support Regeneron's long-term g...
Regeneron Pharmaceuticals, Inc. (REGN) Q4 2025 Earnings Call Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Q4 2025 Earnings Call Transcript
Regeneron bets added cholesterol benefit will help its obesity drug stand out
Regeneron Pharmaceuticals' executives voiced confidence in its experimental weight-loss drug on Friday, saying added cholesterol-lowering benefits could give the company an edge in an increasingly cro...
Regeneron Posts Lower Eylea Sales Amid Rising Competition, Plans $2 Billion New Factory
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) on Friday reported fourth-quarter adjusted earnings of $11.44 per share, down 5% year-over-year, beating the consensus of $10.71.
Regeneron beats quarterly profit estimates on Dupixent strength
U.S. drugmaker Regeneron Pharmaceuticals beat analysts' estimate for fourth-quarter profit on Friday, helped by strong demand for its eczema treatment, Dupixent.
Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
TARRYTOWN, N.Y., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2025 and provided a business up...
Regeneron Pharmaceuticals Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will release earnings results for its fourth quarter, before the opening bell on Friday, Jan. 30.
Regeneron: Q4 Earnings Preview - Why I'm Expecting A Beat And Strong 2026
Regeneron Pharmaceuticals, Inc. is approaching a pivotal earnings report following a strong JP Morgan Healthcare Conference update. I maintain a Buy rating on REGN, supported by a >16% share price gai...
Nation's Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search
Society for Science & Regeneron announced the finalists in the Regeneron Science Talent Search, the nation's oldest and most prestigious STEM competition
Regeneron Pharmaceuticals, Inc. (REGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Final Trades: Capital One, UnitedHealth, Regeneron and Alibaba
The Investment Committee give you their top stocks to watch for the second half.
Regeneron Just Moved From Underperform To Buy - Here's Why
Could the tide be turning for Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) after a surprising shift in analyst sentiment?
Press Release: Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma
Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on global phase 3 program in children demonstrating Dupixent significantly reduce...
Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma
Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo
Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
TARRYTOWN, N.Y., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January ...